Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.
Fiche publication
Date publication
avril 2019
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain, Pr BOUCHE Olivier, Pr GHIRINGHELLI François
Tous les auteurs :
Toulmonde M, Bellera CA, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Le Loarer F, Italiano A
Lien Pubmed
Résumé
CDKN2A loss is frequent in GIST and associated with aggressive outcome. Palbociclib is a CDK4 inhibitor with preclinical anti-tumor efficacy in tumors with P16/CDKN2A loss.
Référence
Clin. Cancer Res.. 2019 Apr 12;: